<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="611">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04558203</url>
  </required_header>
  <id_info>
    <org_study_id>PR0014</org_study_id>
    <nct_id>NCT04558203</nct_id>
  </id_info>
  <brief_title>The Relationship Between COVID-19 and Autoimmune Diseases, Lessons From Practice</brief_title>
  <official_title>The Relationship Between COVID-19 and Autoimmune Diseases, Lessons From Practice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ClinAmygate</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ClinAmygate</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study explore the relationship between COVID-19 and the induction of autoimmune diseases.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It has been suggested that the shared pathogenetic mechanisms and clinical-radiological
      aspects between the hyper-inflammatory diseases and Covid-19 may suggest that SARS-CoV-2
      could act as a triggering factor for the development of a rapid autoimmune and/or
      autoinflammatory dysregulation, leading to the severe interstitial pneumonia, in genetic
      predisposed individuals.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 22, 2020</start_date>
  <completion_date type="Anticipated">October 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 25, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>2 Weeks</target_duration>
  <primary_outcome>
    <measure>incidence of autoimmune conditions</measure>
    <time_frame>Two-weeks</time_frame>
    <description>incidence of autoimmune conditions</description>
  </primary_outcome>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Covid19</condition>
  <eligibility>
    <study_pop>
      <textblock>
        the study population are all patients came to the center with symptoms and signs suspected
        to be COVID-19
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  COVID-19 cases

        Exclusion Criteria:

          -  not proved to be COVID-19 cases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emad R Issak, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asalam Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emad R Issak, MD</last_name>
    <phone>01272228989</phone>
    <email>dr.emad.r.h.issak@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Asalam</name>
      <address>
        <city>Maadi</city>
        <state>Cairo</state>
        <zip>11433</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emad R Issak, MD</last_name>
      <phone>01272228989</phone>
      <email>dr.emad.r.h.issak@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Ehrenfeld M, Tincani A, Andreoli L, Cattalini M, Greenbaum A, Kanduc D, Alijotas-Reig J, Zinserling V, Semenova N, Amital H, Shoenfeld Y. Covid-19 and autoimmunity. Autoimmun Rev. 2020 Aug;19(8):102597. doi: 10.1016/j.autrev.2020.102597. Epub 2020 Jun 11. Review.</citation>
    <PMID>32535093</PMID>
  </reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 19, 2020</study_first_submitted>
  <study_first_submitted_qc>September 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2020</study_first_posted>
  <last_update_submitted>September 22, 2020</last_update_submitted>
  <last_update_submitted_qc>September 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autoimmune Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

